MX2020013205A - Composiciones y metodos para el diagnostico y tratamiento de cancer. - Google Patents
Composiciones y metodos para el diagnostico y tratamiento de cancer.Info
- Publication number
- MX2020013205A MX2020013205A MX2020013205A MX2020013205A MX2020013205A MX 2020013205 A MX2020013205 A MX 2020013205A MX 2020013205 A MX2020013205 A MX 2020013205A MX 2020013205 A MX2020013205 A MX 2020013205A MX 2020013205 A MX2020013205 A MX 2020013205A
- Authority
- MX
- Mexico
- Prior art keywords
- diagnosis
- treatment
- cancer
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2018/065205 WO2019233605A1 (en) | 2018-06-08 | 2018-06-08 | Compositions and methods for diagnosis and treatment of cancer |
| PCT/EP2019/064872 WO2019234190A1 (en) | 2018-06-08 | 2019-06-06 | Compositions and methods for diagnosis and treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013205A true MX2020013205A (es) | 2021-02-26 |
Family
ID=62636178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013205A MX2020013205A (es) | 2018-06-08 | 2019-06-06 | Composiciones y metodos para el diagnostico y tratamiento de cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11673939B2 (https=) |
| EP (1) | EP3802585A1 (https=) |
| JP (1) | JP7466466B2 (https=) |
| KR (2) | KR20240142617A (https=) |
| CN (2) | CN112424220A (https=) |
| AU (1) | AU2019282316B2 (https=) |
| BR (1) | BR112020024034A2 (https=) |
| CA (1) | CA3101246A1 (https=) |
| MX (1) | MX2020013205A (https=) |
| WO (2) | WO2019233605A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019233605A1 (en) * | 2018-06-08 | 2019-12-12 | BioNTech SE | Compositions and methods for diagnosis and treatment of cancer |
| KR102649794B1 (ko) * | 2020-10-19 | 2024-03-22 | 고려대학교 산학협력단 | 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020111302A1 (en) | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
| WO2007004060A2 (en) * | 2005-05-05 | 2007-01-11 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
| EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| CA2741040C (en) * | 2008-10-20 | 2015-09-22 | Gwangju Institute Of Science And Technology | Bipodal-peptide binder |
| CA2822938A1 (en) * | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
| AU2014252354A1 (en) * | 2013-04-11 | 2015-11-19 | Merck Patent Gmbh | Potent inhibitors of human matriptase derived from McotI-II variants |
| WO2016022597A1 (en) * | 2014-08-04 | 2016-02-11 | Case Western Reserve University | Targeting peptides and methods of use |
| WO2016146174A1 (en) | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| US20170218040A1 (en) * | 2016-02-02 | 2017-08-03 | Julio A. Camarero Palao | Proteolically resistant cyclotides with angiotensin 1-7 like activity |
| WO2019233605A1 (en) * | 2018-06-08 | 2019-12-12 | BioNTech SE | Compositions and methods for diagnosis and treatment of cancer |
-
2018
- 2018-06-08 WO PCT/EP2018/065205 patent/WO2019233605A1/en not_active Ceased
-
2019
- 2019-06-06 BR BR112020024034-6A patent/BR112020024034A2/pt not_active Application Discontinuation
- 2019-06-06 EP EP19728093.6A patent/EP3802585A1/en active Pending
- 2019-06-06 WO PCT/EP2019/064872 patent/WO2019234190A1/en not_active Ceased
- 2019-06-06 KR KR1020247031593A patent/KR20240142617A/ko active Pending
- 2019-06-06 CA CA3101246A patent/CA3101246A1/en active Pending
- 2019-06-06 US US16/972,794 patent/US11673939B2/en active Active
- 2019-06-06 AU AU2019282316A patent/AU2019282316B2/en not_active Ceased
- 2019-06-06 CN CN201980045963.4A patent/CN112424220A/zh active Pending
- 2019-06-06 KR KR1020207035142A patent/KR20210020006A/ko not_active Ceased
- 2019-06-06 MX MX2020013205A patent/MX2020013205A/es unknown
- 2019-06-06 JP JP2020568252A patent/JP7466466B2/ja active Active
- 2019-06-06 CN CN202310907634.4A patent/CN116987180A/zh active Pending
-
2023
- 2023-04-20 US US18/303,642 patent/US12516104B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021526808A (ja) | 2021-10-11 |
| JP7466466B2 (ja) | 2024-04-12 |
| EP3802585A1 (en) | 2021-04-14 |
| US20210246191A1 (en) | 2021-08-12 |
| CN116987180A (zh) | 2023-11-03 |
| WO2019233605A1 (en) | 2019-12-12 |
| KR20210020006A (ko) | 2021-02-23 |
| BR112020024034A2 (pt) | 2021-02-23 |
| CA3101246A1 (en) | 2019-12-12 |
| US20240002471A1 (en) | 2024-01-04 |
| CN112424220A (zh) | 2021-02-26 |
| WO2019234190A1 (en) | 2019-12-12 |
| NZ770391A (en) | 2024-09-27 |
| KR20240142617A (ko) | 2024-09-30 |
| US11673939B2 (en) | 2023-06-13 |
| AU2019282316A1 (en) | 2020-12-24 |
| US12516104B2 (en) | 2026-01-06 |
| AU2019282316B2 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001299A (es) | Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas. | |
| ECSP22010228A (es) | Conjugados peptídicos de citotoxinas como terapéuticos | |
| CL2017000864A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| JOP20200142A1 (ar) | بنيات rnai لتثبيط التعبير عن pnpla3 وطرق استخدامها | |
| ECSP17062716A (es) | Heterociclos bicíclicos como inhibidores de fgfr4 | |
| GT201200275A (es) | Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores | |
| MX373103B (es) | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). | |
| CL2016003350A1 (es) | Inhibidores de demetilasa-1 especifica de lisina | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| CR20170060A (es) | Anticuerpos anti tigit | |
| MX374126B (es) | Conjugados de anticuerpo-fármaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada. | |
| BR112017012272A2 (pt) | derivados de 2-anilinopirimidina como moduladores de egfr | |
| CO2019012329A2 (es) | Polipéptidos que antagonizan la señalización wnt en células tumorales | |
| MX350861B (es) | Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos. | |
| GT201200123A (es) | Nuevo uso antitumoral de cabazitaxel | |
| MX2017000168A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| MX377781B (es) | Composiciones y metodos para diagnostico y tratamiento del cancer. | |
| MX2016012933A (es) | Composiciones de relleno de tejidos y metodos de uso. | |
| MX2021002292A (es) | Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa. | |
| MX2020008613A (es) | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer. | |
| UY33174A (es) | Anticuerpo monoclonal anti-factor de necrosis tumoral (tnf), secuencias que lo definen, composiciones que lo comprenden y sus aplicaciones | |
| BR112016013157A2 (pt) | peptídeos resistentes à protease | |
| MX384421B (es) | Ésteres de oxaborol y sus usos. | |
| UY35438A (es) | Procedimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| MX2020013205A (es) | Composiciones y metodos para el diagnostico y tratamiento de cancer. |